Compile Data Set for Download or QSAR
Report error Found 146 Enz. Inhib. hit(s) with all data for entry = 8211
TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236866(US9388162, 73)
Affinity DataKi:  0.320nM ΔG°:  -54.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236867(US9388162, 74)
Affinity DataKi:  0.330nM ΔG°:  -54.1kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236866(US9388162, 73)
Affinity DataEC50:  0.840nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236819(US9388162, 9)
Affinity DataKi:  0.970nM ΔG°:  -51.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236867(US9388162, 74)
Affinity DataEC50:  1.42nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236845(US9388162, 30)
Affinity DataEC50:  1.61nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236832(US9388162, 54)
Affinity DataEC50:  1.81nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236866(US9388162, 73)
Affinity DataEC50:  1.92nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236866(US9388162, 73)
Affinity DataKi:  1.98nM ΔG°:  -53.8kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236853(US9388162, 38)
Affinity DataEC50:  2.30nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236867(US9388162, 74)
Affinity DataEC50:  2.31nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236858(US9388162, 65)
Affinity DataEC50:  2.57nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236846(US9388162, 31)
Affinity DataEC50:  2.59nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236866(US9388162, 73)
Affinity DataEC50:  2.85nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236860(US9388162, 67)
Affinity DataEC50:  3nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236867(US9388162, 74)
Affinity DataEC50:  3.52nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236867(US9388162, 74)
Affinity DataEC50:  3.66nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236863(US9388162, 70)
Affinity DataEC50:  4.01nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236851(US9388162, 36)
Affinity DataEC50:  4.28nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236857(US9388162, 64)
Affinity DataEC50:  4.30nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236857(US9388162, 64)
Affinity DataEC50:  4.71nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236832(US9388162, 54)
Affinity DataEC50:  4.82nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236832(US9388162, 54)
Affinity DataEC50:  5.02nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236864(US9388162, 71)
Affinity DataEC50:  5.60nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236866(US9388162, 73)
Affinity DataEC50:  6.07nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236819(US9388162, 9)
Affinity DataKi:  6.18nM ΔG°:  -50.8kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236864(US9388162, 71)
Affinity DataEC50:  6.76nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236867(US9388162, 74)
Affinity DataKi:  7.42nM ΔG°:  -50.3kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236859(US9388162, 66)
Affinity DataEC50:  7.57nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236862(US9388162, 69)
Affinity DataEC50:  9.52nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236845(US9388162, 30)
Affinity DataEC50:  9.61nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236846(US9388162, 31)
Affinity DataEC50:  9.65nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236853(US9388162, 38)
Affinity DataEC50:  10.3nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236849(US9388162, 34)
Affinity DataEC50:  12.6nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236851(US9388162, 36)
Affinity DataEC50:  12.7nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236850(US9388162, 35)
Affinity DataEC50:  13.6nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236832(US9388162, 54)
Affinity DataEC50:  14.2nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236844(US9388162, 29)
Affinity DataEC50:  14.6nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236819(US9388162, 9)
Affinity DataEC50:  17.3nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236847(US9388162, 32)
Affinity DataEC50:  17.5nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236847(US9388162, 32)
Affinity DataEC50:  18.6nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236861(US9388162, 68)
Affinity DataEC50:  20.5nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236842(US9388162, 27)
Affinity DataEC50:  24.7nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236843(US9388162, 28)
Affinity DataEC50:  27.1nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236848(US9388162, 33)
Affinity DataEC50:  36.1nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236829(US9388162, 48)
Affinity DataEC50:  38.6nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236852(US9388162, 37)
Affinity DataEC50:  42.1nMpH: 7.4 T: 2°CAssay Description:Functional [35S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236823(US9388162, 15)
Affinity DataEC50:  43.8nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236827(US9388162, 19)
Affinity DataEC50:  49.7nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM236829(US9388162, 48)
Affinity DataKi:  65.3nM ΔG°:  -41.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

Displayed 1 to 50 (of 146 total ) | Next | Last >>
Jump to: